Form 4: Nuvalent Director Emily Conley Executes Stock Option and Sells Shares Under 10b5-1 Plan

Director Emily Conley exercised stock options and sold shares of Nuvalent, Inc. under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 15, 2024, Emily Conley, a director of Nuvalent, Inc., executed a transaction involving the company's Class A Common Stock.
• Conley exercised a stock option to acquire 5,000 shares at a price of $9.36 per share.
• Simultaneously, Conley sold 4,994 shares at a weighted average price of $65.52 and 6 shares at a weighted average price of $66.66.
• These transactions were executed under a pre-existing Rule 10b5-1 trading plan adopted on December 13, 2023.
• Following these transactions, Conley directly owns 14 shares of Class A Common Stock and 1,667 stock options.

Sentiment

Score: 6

Explanation: Neutral sentiment as the filing reflects routine insider transactions under a pre-arranged plan. No indication of unusual activity or concerns.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• While the transactions are under a 10b5-1 plan, large sales by insiders can sometimes be perceived negatively by the market.

Industry Context

Form 4 filings are standard disclosures for corporate insiders and provide transparency into their trading activities. The use of a 10b5-1 plan is a common practice to avoid insider trading accusations.

Comparison to Industry Standards

• Directors and officers at comparable pharmaceutical companies like Relay Therapeutics or Black Diamond Therapeutics routinely use 10b5-1 plans for stock transactions.
• The reported weighted average sale prices are within the typical range observed for similar transactions in the biotech sector.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the director's stock sales, but the 10b5-1 plan mitigates concerns.

Key Dates